Search results
Results from the WOW.Com Content Network
Escalating concerns regarding the safety of ephedra supplements led the FDA to ban the sale of supplements containing ephedrine alkaloids (specifically ephedrine, pseudoephedrine, norephedrine, and methylephedrine) in the United States in 2004. This ban was challenged by supplement manufacturers and initially overturned, but ultimately upheld.
Following the FDA's ban of ephedra, Michael Ellis was indicted on eight counts of making false statements to the FDA in an effort to obstruct regulation of ephedra. [22] [23] Ellis ultimately pled guilty to a single count of lying to the FDA about the adverse effects of Metabolife 356. He was sentenced to 6 months in federal prison and a ...
The Food and Drug Administration, which had previously chosen not to ban ephedra, subsequently re-opened its efforts to regulate it. The United States Congress dropped its previous objections to a ban, and Bechler's parents testified in front of Congress. [18] The FDA announced its decision to ban ephedra on December 30. [24]
For premium support please call: 800-290-4726 more ways to reach us
In 1997, the FDA proposed a regulation on ephedra (the herb from which ephedrine is obtained), which limited an ephedra dose to 8 mg (of active ephedrine) with no more than 24 mg per day. [78] This proposed rule was withdrawn, in part, in 2000 because of "concerns regarding the agency's basis for proposing a certain dietary ingredient level and ...
In fact, in 2004, ephedra was banned by the FDA for use in diet and sports supplements because it showed to have serious health risks like heart attack and stroke, resulting in deaths. Physicians ...
The FDA bans the import and use of tonka extract — and its liver-attacking passenger coumarin — for all uses in food. More From GOBankingRates. How Long $1 Million in Savings Will Last in ...
In 2004, FDA banned a second Dexatrim ingredient, ephedra. Although ephedra showed some effectiveness for short-term weight loss, [17] it was linked to raising blood pressure and increasing the risk of heart problems and stroke. [18] In March 2014, Chattem sold Dexatrim to NVE Pharmaceuticals. [19]